Reuters logo
BRIEF-Arbutus announces topline results for ARB-1467 phase II Cohort 4
September 25, 2017 / 12:49 PM / a month ago

BRIEF-Arbutus announces topline results for ARB-1467 phase II Cohort 4

Sept 25 (Reuters) - Arbutus Biopharma Corp:

* Arbutus Biopharma Corp announces topline results for ARB-1467 phase ii cohort 4

* Arbutus Biopharma Corp - seven of the twelve patients met the predefined response criteria at or before day 71

* Arbutus -initial results for monthly dosing extension suggest monthly dosing not sufficient to maintain/improve on reductions in s-antigen levels

* Arbutus Biopharma - detailed results of cohort 4 are expected to be presented at AASLD in October

* Arbutus Biopharma - planning to initiate new study of ARB-1467 in Q4 to evaluate longer dosing of ARB-1467 combined with Interferon

* Arbutus Biopharma Corp - all 12 patients in cohort 4 experienced reductions in serum HBsAg levels

* Arbutus Biopharma - to initiate new study in Q4 to study longer term Bi-weekly dosing of ARB-1467 in combination with Tenofovir Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below